@article{f6b8a1197f0f45d2a47a8a2519257410,
title = "Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-matched Analysis",
keywords = "Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Female, Fluorouracil/therapeutic use, Follow-Up Studies, Humans, Irinotecan/therapeutic use, Leucovorin/therapeutic use, Male, Middle Aged, Neoplasm Staging, Netherlands/epidemiology, Oxaliplatin/therapeutic use, Pancreas/pathology, Pancreatectomy/methods, Pancreatic Neoplasms/diagnosis, Propensity Score, Prospective Studies, Survival Rate/trends, SURGERY, FOLFIRINOX, locally advanced pancreatic cancer, QUALITY-OF-LIFE, BORDERLINE, ADENOCARCINOMA, NEOADJUVANT THERAPY, resection, IMPACT, OUTCOMES",
author = "Brada, {Lilly J H} and Daamen, {Lois A} and Magermans, {Lisa G} and Walma, {Marieke S} and Diba Latifi and {van Dam}, {Ronald M} and {de Hingh}, {Ignace H} and Liem, {Mike S L} and {de Meijer}, {Vincent E} and Patijn, {Gijs A} and Sebastiaan Festen and Stommel, {Martijn W J} and Koop Bosscha and Pol{\'e}e, {Marco B} and Nio, {Yung C} and Wessels, {Frank J} and {de Vries}, {Jan J J} and {van Lienden}, {Krijn P} and Bruijnen, {Rutger C} and Busch, {Olivier R} and Koerkamp, {Bas Groot} and {van Eijck}, Casper and Molenaar, {Quintus I} and Wilmink, {Hanneke J W} and {van Santvoort}, {Hjalmar C} and Besselink, {Marc G} and {Dutch Pancreatic Cancer Group}",
note = "Copyright {\textcopyright} 2021 Wolters Kluwer Health, Inc. All rights reserved.",
year = "2021",
month = nov,
day = "1",
doi = "10.1097/SLA.0000000000005120",
language = "English",
volume = "274",
pages = "729--735",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "LIPPINCOTT WILLIAMS & WILKINS",
number = "5",
}